Children who have taken psychostimulants long term for attention deficit/hyperactivity disorder (ADHD) are now presenting at adult psychiatry clinics at an age at which bipolar disorder and schizophrenia may first appear and at which pregnancy is a possibility. Doctors who may have little experience in the management of ADHD or use of psychostimulants are faced with decisions on whether to continue or withdraw medication. A literature search conducted to clarify these issues revealed that, although psychostimulants are generally efficacious in ADHD, the risks of withdrawal reactions and of possible long-term effects such as drug addiction, psychosis and depression, or effects in pregnancy, have not been adequately investigated. In particular, there is little information on the effects of withdrawal and no firm guidelines on methods of psychostimulant discontinuation. There is a need for further research to clarify the pharmacological issues involved in the drug treatment of ADHD and for overlapping arrangements between child and adult psychiatry clinics in the management of ADHD.
Achenbach T M , Howell C , McConaughy S , Stanger C (1998) Six-year predictors of problems in a national sample, IV: young adult signs of disturbance . J Am Acad Child Adolesc Psychiatry37: 718–727
2.
Adler L A , Spencer T J , Milton D R , Moore R J , Michelson D (2005) Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis . J Clin Psychiatry66: 294–299
3.
American Pregnancy Association (2005) Using illegal street drugs during pregnancy. Available online at www.american%20pregnancy.org. (accessed April 2005)
4.
Andersen S L (2005) Stimulants and the developing brain . Trends Pharm Sci26: 237–243
5.
Andersen S L , Navalta C P (2004) Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs . Int J Devel Neurosci22: 423–440
6.
Arnold L E , Lindsey R L , Conners C K , Wigal S B , Levine A J , Johnson D E , West S A , Sangal R B , Bohan T P , Zeldis J B (2004) A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder . J Child Adolesc Psychopharmacol14: 542–544
7.
Ashton C H (1985) Disorders of the fetus and infant. In Davies D M (ed.), Textbook of Adverse Drug Reactions. 3rd edn.Oxford University Press, Oxford , pp. 77–127
8.
Ashton C , Young A H (1999) SSRIs, drug withdrawal and abuse: problem or treatment? In Stanford S C (ed.), Selective Serotonin Reuptake Inhibitors (SSRIs) Past, Present and Future. R.G. Landes Co., Austin, TX , pp. 65–80
9.
Barkley R A (1997) Behavioral inhibition, sustained attention and executive functions: constructing a unifying theory of ADHD . Psychol Bull121: 65–94
10.
Barton J (2005) Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder . Arch Dis Child90 (Suppl. 1): i26–i29
11.
Biederman J , Faraone S V (2005) Attention-deficit hyperactivity disorder . Lancet366: 237–248 .
12.
Biederman J , Spencer T J (2004) Psychopharmacology of adults with attention-deficit/hyperactivity disorder . Primary Psychiatry11: 57–62
13.
Biederman J , Wilens T , Mick E , Spencer T , Faraone S V (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder . Pediatrics104: e20-e20
14.
Biederman J , Faraone S , Milberger S , Curtis S , Chen L , Marrs A (1996) Predictors of persistence and remission of ADHD into adolescence: results from a four year prospective follow-up study . J Am Acad Child Adolesc Psychiatry35: 343–351
15.
Biederman J , Faraone S V , Spencer T , Wilens T , Norman D , Lapey K A , Lehman B K , Doyle A (1993) Patterns of psychiatric comorbidity, cognition and psychosocial functioning in adults with attention deficit hyperactivity disorder . Am J Psychiatry150: 1792–1798
16.
Bolanos C A , Barrot M , Berton O , Wallace-Black D , Nestler E J (2003) Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood . Biol Psychiatry54: 1317–1329
17.
Brandon C L , Marinelli M , White F J (2003) Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons . Biol Psychiatry15: 1338–1344
18.
Brown R T , Amler R W , Freeman W S , Perrin J M , Stein M T , Feldman H M , Pierce K , Wolraich M L , Committee on Quality Improvement , Sub-committee on Attention Deficit/Hyperactivity Disorder (2005) Treatment of attention deficit/hyperactivity disorder: Overview of the evidence . Pediatrics115: e749–e757
19.
Calello D P , Osterhoudt K C (2004) Acute psychosis associated with therapeutic use of dextroamphetamine . Pediatrics113: 1466-1466 .
20.
Carlezon W A , Mague S D , Anderson S L (2003) Enduring behavioral effects of early exposure to methylphenidate in rats . Biol Psychiatry54: 1330–1337
21.
Castellanos F X , Lee P P , Sharp W , Jeffries N O , Greenstein D K , Clasen L S , Bumenthal J D , James R S , Ebens C L , Walter J M , Zijdenbos A , Evans A C , Giedd J N , Rapaport J L (2002) Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder . JAMA288: 1740–1748
22.
Christman A K , Fermo J D , Markowitz J S (2004) Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder . Pharmacotherapy24: 1020–1036
23.
Cocores J , Pottash J C , Gold S (1991) Cocaine. In Miller N S (ed.), Comprehensive Handbook of Drug and Alcohol Addiction. Marcel Dekker Inc., New York , pp. 341–352
24.
Coghill D , Markowitz H (2004) Use of stimulants for attention deficit hyperactivity disorder . Br Med J329: 907–909
25.
Cohen D , Leo J , Stanton T , Stanton T , Smith D , McCready K , Laing M S , Stein D B , Oas P , Kean B , Parry S (2002) A boy who stops taking stimulants for ‘ADHD’: Commentaries on a Pediatrics case study . Ethical Human Sciences and Services4: 189–209
26.
DiMaio S , Grizenko N , Jooper R (2003) Dopamine genes and attentiondeficit hyperactivity disorder: a review . J Psychiatry Neurosci28: 27–38
27.
Dougherty D D , Bonab A A , Spencer T J , Rauch S L , Madras B K , Fischman A J (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder . Lancet354: 2132–2133
28.
Faraone S V , Biederman J (2002) Pathophysiology of attention deficit hyperactivity disorder. In Davis K L , Charney D , Coyle J T , Nemeroff C (eds), Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott & Wilkins, Philadelphia, PA , pp. 577–596
29.
Faraone S , Biederman J , Chen W J , Krifcher B , Keenan K , Moore C , Sprich S (1992) Segregation analysis of attention deficit hyperactivity disorder . Psychiatr Genet2: 257–275
30.
Faraone S V , Biederman J , Roe C (2002) Comparative Efficacy of Adderall and Methylphenidate in Attention-deficit/Hyperactivity Disorder: A Meta-analysis . J Clin Psychopharm22: 468–473
31.
Faraone V , Faraone R H , Perlis R H , Doyle A E , Smoller J W , Goralnick J J , Holmgren M A , Sklar E (2005) Molecular genetics of attention-deficit/hyperactivity disorder .Biol Psychiatry57: 1313–1323
32.
Ferner R E (1998) Disorders of the fetus and infant. In Davies D M , Ferner R E , de Glanville H (eds), Textbook of Adverse Drug Reactions. 5th edn.Chapman and Hall Medical, London , pp. 82–128
33.
Fone C F , Nutt D J (2005) Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder . Curr Opin Pharm5: 87–93
34.
Giedd J N , Blumenthal J , Molloy E , Castellanos F X (2001) Brain imaging of attention deficit/hyperactivity disorder . Ann N Y Acad Sci931: 33–49
35.
Giedd J N , Blumenthal J , Jeffries N O , Castellanos F X , Liu H , Zijdenbos A , Paus T , Evans A C , Rapaport J L (1999) Brain development during childhood and adolescence: a longitudinal MRI study . Nature Neurosci2: 861–863
36.
Gifford A N , Park M H , Kash T L , Herman L M , Park E H , Gatley S J , Volkow N D (2000) Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices . Naunym Schmiederbergs Arch Pharmacol362: 413–418
37.
Gordon S M , Tulak F , Troncale J (2004) Prevalence and characteristics of adolescent patients with co-occurring ADHD and substance dependence . J Addict Dis23: 31–40
38.
Gross-Tsur V , Joseph A , Shalev R S (2004) Hallucinations during methylphenidate therapy . Neurology63: 753–754
39.
Harpin V (2005) Atomoxetine: a new choice for the treatment of ADHD . Prescriber, 16: 12–16
40.
Johnson M H (2003) Development of human brain functions . Biol Psychiatry54: 1312–1316
41.
Keating G M , Figgitt D P (2002) Dexmethylphenidate . Drugs62: 1899–1904
42.
Klein R G , Landa B , Mattes J A , Klein D F (1988) Methylphenidate and growth in hyperactive children. A controlled withdrawal study . Arch Gen Psychiatry45: 1127–1130
43.
Klein-Schwartz W (2002) Abuse and toxicity of methylphenidate . Curr Opin Pediatr14: 219–223
44.
Klein-Schwartz W , McGrath J (2003) Poison centers' experience with methylphenidate abuse in pre-teens and adolescents . J Am Acad Child Adolesc Psychiatry42: 288–294
45.
Kooij J J S , Burger H , Boonstra A M , Van Der Linden P D , Kalma L E , Buitelaar J K (2004) Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial . Psychological Medicine34: 973–982
46.
Krause K-H , Dresel S H , Krause J , la Fouger C , Ackenheil M (2003) The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder . Neurosci Behav Rev27: 605–613
47.
Kutcher S , Aman M , Brooks S J , Buitelaar J , van Daalen E , Fegert J , Findling R L , Fisman S , Greenhill L L , Huss M , Kusumakar V , Pine D , Taylor E , Tyano S (2004) International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions . Eur Neuropsychopharm14: 11–28
48.
Leonard B E , McCartan D , White J , King D J (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects . Human Psychopharm Clin Exp19: 151–180
49.
London E , Simon S L , Berman S M , Mandelker M A , Lightman A M , Bramen J , Shinn A K , Miotto K , Learn J , Dong Y , Matochik J A , Kurian V , Newton T , Woods R , Rawson R , Ling W (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers . Arch Gen Psychiat61: 73–84
50.
McGough J J , Barkley R A (2004) Diagnostic controversies in adult deficit hyperactivity disorder . Am J Psychiatry161: 1948–1956
51.
Madras B K , Miller G M , Fischman A J (2005) The dopamine transporter and attention-deficit/hyperactivity disorder . Biol Psychiatry57: 1397–1409
52.
Mague S D , Andersen S L , Carlezon W A (2005) Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats . Biol Psychiatry57: 120–125
53.
March of Dimes (2005) Cocaine use during pregnancy. Available online at www.marchofdimes.com. (accessed April 2005)
54.
Martins S , Tramontina S , Polanczyk G , Eizirik M , Swanson J M , Rohde L A (2004) Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial . J Child Adolesc Psychopharmacol14: 195–206
55.
Massello W 3rd , Carpenter D W (1999) A fatality due to the intranasal abuse of methylphenidate (Ritalin) . J Forensic Sci44: 220–221
56.
MHRA Press Release Medical and Health Care Products Agency (2005) Updated warnings on the risk of suicidal thoughts with Strattera. Available online at Press.office@mhra.gsi.gov.uk
57.
Miller N S (1991) Amphetamines. In Miller N S (ed.), Comprehensive Handbook of Drug and Alcohol Addiction. Marcel Dekker Inc., New York , pp. 427–436
58.
Millstein R B , Wilens T E , Biederman J , Spencer T J (1997) Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD . J Affect Disord2: 159–166
59.
Mohammadi M R , Ghanizadeh A , Alaghband-Rad J , Tehranidost M , Mesgarpour B , Soori H (2004) Selegiline in comparison with methylphenidate in attention deficit/hyperactivity disorder children and adolescents in a double-blind randomized clinical trial . J Child Adolesc Psychopharmacol14: 418–425
60.
MTA Cooperative Group (2004) National Institute of Mental Health multimodal treatment study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder . Pediatrics113: 754–761
61.
Naeye R L (1983) Maternal use of dextroamphetamine and growth of the fetus . Pharmacology26: 117–120 .
62.
National Institute for Clinical Excellence (NICE) (2003) Guidelines on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. Technology Appraisal Guidance No. 13
63.
Niederhofer H , Staffen W , Mair A (2003) A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder . J Psychopharmnacol17: 113–119
64.
Papazian O , Alfonso I , Garcia V (2002) The effect of discontinuation of methylphenidate at adolescence onset on adult attention deficit hyperactivity disorder . Rev Neurol35: 24–28
65.
Pelham W E , Manos M J , Ezzell C E , Tresco K E , Gnagy E M , Hoffman M T , Onyango A N , Fabiano G A , Lopez-Williams A , Wymbs B T , Caserta D , Chronis A M , Burrows-Maclean L , Morse G (2005) A dose-ranging study of a methylphenidate transdermal system in children with ADHD . J Am Acad Child Adolesc Psychiatry44: 522–529
66.
Pliszka S R (2005) The neuropsychopharmacology of attention-deficit/hyperactivity disorder . Biol Psychiatry57: 1385–1390
67.
Poulton A (2005) Growth on stimulant medication; clarifying the confusion: a review . Arch Dis Childhood90: 801–806
68.
Prescriber (2005) New once-daily methylphenidate . Prescriber16: 10-10
69.
Purper-Ouakil D , Fourneret P , Wohl M , Reneric J P (2005) Atomoxetine: a new treatment for attention deficit/hyperactivity disorder (ADHD) in children and adolescents . Encephale31: 337–348
70.
Ratner S , Laor N , Bronstein Y , Weizman A , Toren P (2005) Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder . J Am Acad Child Adolesc Psychiatry44: 428–433
71.
Raz A (2004) Brain imaging data of ADHD. Psychiatric TimesXXI, Issue 9
72.
Reeves G , Schweitzer J (2004) Pharmacological management of attention-deficit hyperactivity disorder . Expert Opin Pharmacother5: 1313–1320
73.
Rosenfeld A A (1979) Depression and psychotic regression following prolonged methylphenidate use and withdrawal: Case report . Am J Psychiatry136: 226–228
74.
Ross D C , Fischoff J , Davenport B (2002) Treatment of ADHD when tolerance to methylphenidate develops . Psychiatr Ser53: 102-102
75.
Sanz E J , De-lasCuevas C , Kiuru A , Bate A , Edwards R (2005) Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis . Lancet365: 482–487
76.
Sarampote C S , Efron L A , Robb A S , Pearl P L , Stein M A (2002) Can stimulant rebound mimic pediatric bipolar disorder?J Child Adolesc Psychopharmacol12: 63–67
77.
Schteinschnaider A , Plaghos L L , Garbugno S , Riveros D , Lazarowski A , Intruvini S , Massaro M (2000) Cerebral arteritis following methylphenidate use . J Child Neurol15: 265–267
78.
Schwartz R H , Rushton H G (2004) Stuttering priapism associated with withdrawal from sustained-release methylphenidate . J Pediatr144: 6575–6576
79.
Schweitzer J B , Lee D O , Hanford R B , Zink C F , Ely T D , Tagamets M A , Hoffman J M , Grafton S T , Kilts C D (2004) Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: Normalization of behavior but not related brain activity . Biol Psychiatry56: 597–606
80.
Scottish Intercollegiate Guidelines Network (2001) Attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline. SIGN Guideline No. 52-52
81.
Sevecke K , Battel S , Dittmann R W , Lehmkuhl G , Dopfner M (2005) The effectiveness of atomoxetine in children, adolescents, and adults with ADHD: a systematic overview. Der Nervenarzt [Epub ahead of print]
82.
Shetty H G M , Routledge P A , Davies D M (1998) Disorders of muscle, bone and connective tissues. In Davies D M , Ferner R E , de Glanville H (eds), Textbook of Adverse Drug Reactions. Chapman and Hall Medical, London , pp. 541–565
83.
Sonuga-Barke E J S (2002) Psychological heterogeneity in AD/HD – a dual pathway model of behaviour and cognition . Behavioural Brain Research130: 29–36
84.
Spear J , Alderton D (2003) Psychosis associated with prescribed dexamphetamine use . Aust N Z J Psychiatry37: 383-383
85.
Spencer T , Biederman J , Wilens T (2004) Nonstimulant treatment of adult attention-deficit/hyperactivity disorder . Psychiatr Clin North Am27: 373–383
86.
Spencer T , Biederman J , Wilens T , Doyle R , Surnam C , Prince J , Mick E , Aleardi M , Herzig K , Faraone S (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder . Biological Psychiatry57: 456–463
87.
Stein M T , Shafer G R , Levine S (1999) An adolescent who abruptly stops his medication for attention-deficit hyperactivity disorder . Developmental and Behavioral Pediatrics20: 106–110
88.
Stoops W W , Glaser P E A , Fillmore M T , Rush C R (2004) Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J . Psychopharmacol18: 534–543
89.
Stoops W W , Lile J A , Fillmore M T , Glaser P E , Rush C R (2005) Reinforcing effects of methylphenidate: influence of dose and behavioral demands following drug administration . J Psychopharmacol (Berl) 18: 349–355
90.
Surles L K , May H J , Garry J P (2002) Adderall-induced psychosis in an adolescent . J Am Board Fam Pract15: 498–500
91.
Thalhammer C , Aschwanden M , Kliem M , Sturchler M , Jagger K A (2004) Acute ischaemia after intra-arterial drug injection . Dtsch med Wochenschr129: 2405–2408
92.
Titmarsh S (2004) Something new – really . Progress in Neurology and Psychiatry8: 7–8
93.
Vastag B (2001) Pay attention: Ritalin acts much like cocaine . JAMA286: 905–906
94.
Volkow N D , Insell T R (2003) What are the long-term effects of methylphenidate treatment?Biol Psychiatry54: 1307–1309
95.
Volkow N D , Fowler J S , Wang G J (1999a) Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans . J Psychopharmacol13: 337–345
96.
Volkow N D , Wang G-J , Fowler J S , Ding Y-S (2005) Imaging the effects of methylphenidate on brain dopamine: New model on its therapeutic actions for attention-deficit/hyperactivity disorder . Biol Psychiatry57: 1410–1415
97.
Volkow N D , Wang G J , Fowler J S , Logan J , Gatley S J , Wong C , Hitzermann P , Pappaz N R (1999b) Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors . J Pharmacol Exp Ther291: 409–415
98.
Volkow N D , Wang G , Fowler J S , Logan J , Gerasimov M , Maynard L , Ding Y-S , Gatley S J , Gifford A , Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain . J Neurosci21: RC121-RC121, 1–5
99.
Volkow N D , Wang G J , Fowler J S , Gatley S J , Logan D , Ding Y S , Gatley S J , Logan J , Ding Y S , Hitzermann R , Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate . Am J Psychiatry155: 1325–1331
100.
Waldman D , Rowe D C , Abramowitz A , Kozel S T , Mohr J H , Sherman S L , Cleveland H H , Sanders M L , Gard J M C , Stever C (1998) Associ ation and linkage of the dopamine transporter gene and attentiondeficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity . Am J Hum Genet63: 1767–1776
101.
Weiss G , Hechtman L , Milroy T , Periman T (1985) Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children . J Am Acad Child Psychiatry24: 211–220
102.
Weiss M , Tannock R , Kratochvil C , Dunn D , Velez-Borras J , Thomason C , Tamura R , Selsey D , Stevens L , Allen A J (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD . J Am Acad Child Adolesc Psychiatry44: 647–655
103.
Wender P H , Wolf L E , Wasserstein J (2001) Adults with ADHD. An overview . Ann N Y Acad Sci93: 1–16
104.
Wilens T (2003) Drug therapy for adults with attention deficit hyperactivity disorder . Drugs63: 2395–2411
105.
Wilens T E (2004) Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, who is at risk, and treatment issues . Primary Psychiatry11: 63–70
106.
Wilens T E , Faraone S V , Biederman J (2004) Attention-deficit/hyperactivity disorder in adults . JAMA292: 619–623
107.
Wilens T E , Faraone S V , Biederman J , Gunwardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later sub-stance abuse? A meta-analytic review of the literature . Pediatrics111: 179–186
